Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC

Saved in:
Bibliographic Details
Published in:J Immunother Cancer
Main Authors: Rizvi, Naiyer, Barlesi, Fabrice, Brahmer, Julie, Felip, Enriqueta, Forde, Patrick, Garassino, Marina, Goldberg, Sarah, Vansteenkiste, Johan, Jarkowski, Anthony, McIntosh, Stuart, Zhao, Luping, Antonia, Scott
Format: Artigo
Language:Inglês
Published: BioMed Central 2015
Subjects:
Poster Presentation
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4646121/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2051-1426-3-S2-P171
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items